Commercial insulin immunoassays fail to detect commonly prescribed insulin analogues.

@article{Parfitt2015CommercialII,
  title={Commercial insulin immunoassays fail to detect commonly prescribed insulin analogues.},
  author={Clare Parfitt and David H. Church and Annie E Armston and Lewis Couchman and Carol Evans and Gwen Wark and Timothy J McDonald},
  journal={Clinical biochemistry},
  year={2015},
  volume={48 18},
  pages={1354-7}
}
OBJECTIVES Blood insulin and C-peptide are key investigations in the differential diagnosis of hypoglycaemia. Analogues of insulin have modified primary-sequences compared to native human insulin, as such may not cross react with insulin assays. This has important implications in detecting surreptitious or malicious insulin administration. The aim of this study is to assess the cross-reactivity of all insulins currently listed in the British National Formulary (BNF65, 2013) in clinical insulin… CONTINUE READING